Enimmune Statistics

Total Valuation

Enimmune has a market cap or net worth of TWD 1.37 billion. The enterprise value is 1.31 billion.

Market Cap	1.37B
Enterprise Value	1.31B

Important Dates

The next estimated earnings date is Tuesday, August 11, 2026.

Earnings Date	Aug 11, 2026
Ex-Dividend Date	n/a

Share Statistics

Enimmune has 72.13 million shares outstanding. The number of shares has increased by 0.86% in one year.

Current Share Class	72.13M
Shares Outstanding	72.13M
Shares Change (YoY)	+0.86%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.74%
Owned by Institutions (%)	3.87%
Float	30.85M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	28.36
PB Ratio	9.13
P/TBV Ratio	27.01
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-7.99
EV / Sales	27.23
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-8.90

Financial Position

The company has a current ratio of 1.16, with a Debt / Equity ratio of 1.14.

Current Ratio	1.16
Quick Ratio	0.99
Debt / Equity	1.14
Debt / EBITDA	n/a
Debt / FCF	-1.16
Interest Coverage	-46.16

Financial Efficiency

Return on equity (ROE) is -52.33% and return on invested capital (ROIC) is -25.50%.

Return on Equity (ROE)	-52.33%
Return on Assets (ROA)	-19.63%
Return on Invested Capital (ROIC)	-25.50%
Return on Capital Employed (ROCE)	-101.56%
Weighted Average Cost of Capital (WACC)	5.69%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	38
Asset Turnover	0.08
Inventory Turnover	1.41

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -0.27% in the last 52 weeks. The beta is 0.35, so Enimmune's price volatility has been lower than the market average.

Beta (5Y)	0.35
52-Week Price Change	-0.27%
50-Day Moving Average	18.42
200-Day Moving Average	19.21
Relative Strength Index (RSI)	52.47
Average Volume (20 Days)	132,282

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Enimmune had revenue of TWD 48.19 million and -164.35 million in losses. Loss per share was -2.28.

Revenue	48.19M
Gross Profit	8.02M
Operating Income	-185.24M
Pretax Income	-164.54M
Net Income	-164.35M
EBITDA	-179.22M
EBIT	-185.24M
Loss Per Share	-2.28

Full Income Statement

Balance Sheet

The company has 225.79 million in cash and 171.19 million in debt, giving a net cash position of 54.59 million or 0.76 per share.

Cash & Cash Equivalents	225.79M
Total Debt	171.19M
Net Cash	54.59M
Net Cash Per Share	0.76
Equity (Book Value)	149.69M
Book Value Per Share	2.08
Working Capital	44.47M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -143.25 million and capital expenditures -4.18 million, giving a free cash flow of -147.43 million.

Operating Cash Flow	-143.25M
Capital Expenditures	-4.18M
Depreciation & Amortization	6.02M
Net Borrowing	53.21M
Free Cash Flow	-147.43M
FCF Per Share	-2.04

Full Cash Flow Statement

Margins

Gross Margin	16.63%
Operating Margin	-384.37%
Pretax Margin	-341.41%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Enimmune does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.86%
Shareholder Yield	-0.86%
Earnings Yield	-12.02%
FCF Yield	-10.79%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Enimmune has an Altman Z-Score of -0.04 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.04
Piotroski F-Score	2